BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion

BERKELEY, CA and VANCOUVER, BC --(Marketwired - February 27, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the "Offering") of 5,416,667 units of the Company (the "Units") at a price of C$0.24 per Unit for aggregate gross proceeds of C$1,300,000. Under the terms of the Offering, each Unit shall consist of one common share in the capital of the Company (a "Common Share") and one-half of a Common Share purchase warrant (a "Warrant"). Each Warrant will be exercisable for one Common Share at an exercise price of C$0.35. The Warrants will be exercisable for 24 months following the date of closing of the Offering. The Offering is subject to the approval of the TSX Venture Exchange and other customary closing conditions.

The Company intends to use proceeds from the Offering to advance the Company's ongoing Phase I/IIa clinical trial of BriaVax™, for advancing the BriaCell R&D clinical program, companion diagnostic platform known as BriaDx™, and pipeline expansion.

"I hope my financial investment together with a full commitment to BriaCell reflects my confidence in the long-term value of the Company, its technology, business model, management team, and strong growth prospects," commented Dr. Williams, BriaCell's CEO. "My investment in BriaCell's shares at a premium price upholds my belief that the current market valuation does not reflect the fundamentals of the Company and its growth potential."

BriaCell recently submitted a Chemistry, Manufacturing, and Controls (CMC) amendment which includes the details of extensive testing performed on BriaVax™, the Company's proprietary vaccine for advanced breast cancer. Pending the authorization by the FDA, BriaCell plans to proceed with the initiation of the Phase I/IIa Clinical Study for BriaVax™ in advanced breast cancer within this quarter. BriaVax™ is a genetically engineered whole-cell vaccine derived from a human breast tumor cell line. It is believed to activate the immune system to recognize and eliminate cancerous cells by inducing tumor directed T cell and antibody responses.